Project Grant HT94252410755
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award for $699,750 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the University of Washington aims to support the discovery and characterization of tissue-specific regulatory mutations that predispose to ovarian cancer. The award will fund research activities over a 3-year period from April 2024 to March 2027. As a leading research university, the University of Washington has extensive experience managing federal grants and...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award of $932,918 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Washington to determine the role of somatic mosaicism in ovarian cancer predisposition. The grant, awarded on September 30, 2024 with an ultimate completion date of September 29, 2028, will enable the University of Washington to conduct innovative scientific studies to improve health outcomes for military...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...
This federal Project Grant award, totaling $3,560,880, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the public. The primary awardee, the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will conduct sophisticated scientific investigations to address various medical...
The University of Washington was awarded a $1,312,384 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from August 1, 2022 to July 31, 2025 to target FZD6 sensitization of advanced prostate cancer to genotoxic stress. Through this funding, researchers at the University of Washington aim to investigate medical solutions for prostate cancer by exploring how targeting...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,312,000.00 to The Regents of the University of California, San Francisco to conduct research on strategies to upregulate and image Nectin4 to enhance Nectin4-targeted therapies in bladder cancer. The award period runs from August 1, 2025 to July 31, 2029. The goal of this research is to advance scientific understanding and develop potential...
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...
The U.S. Department of Defense's Defense Health Agency awarded a $526,042 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to support research aimed at identifying and targeting mechanisms of prostate cancer therapy resistance driven by the tumor microenvironment. The project will be conducted over a 2-year period from May 1, 2024 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). This research grant...